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Abstract 
Background and objectives: There is evidence that the incidence of solid tumors is markedly 
increased in patients with diabetes mellitus. In the current study, we investigate the associa-
tion between diabetes and renal cancer. 
Patients and Methods: A single-center retrospective analysis of 473 patients who underwent 
nephrectomy for renal cell carcinoma (RCC) was performed. Diabetic RCC patients were 
screened for age, gender, ethnicity, HgA1C, glucose levels and renal function. 
Results: Of the 473 cases with RCC, we identified 120 patients (25.4%) with a history of 
diabetes. The incidence of diabetes in RCC patients was higher in female than male subjects 
and in Hispanic compared to White and Other ethnic backgrounds. At diagnosis, the majority 
of diabetic RCC patients were 50-59 years of age. In diabetic RCC cases, clear cell type 
histology (92.0%), nuclear grade 2 (56.1%) and tumor size range from 1-5 cm (65.7%) were the 
most common in each category. 
Conclusion: Our findings indicate that diabetic RCC patients have a predominance of local-
ized, small clear cell RCC. In addition, females with a history of RCC have a higher frequency 
of diabetes compared to males. This is the first report of clinical and histopathological features 
of RCC associated with diabetes. 
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1. Introduction 
Epidemiologic studies have shown that patients 
with type 1 and type 2 diabetes mellitus (DM) are at 
higher risk than the general population for develop-
ing certain malignancies including kidney, liver, bili-
ary tract, pancreas and colon [1-6]. In diabetics, cancer 
contributes 13% to mortality and these patients suffer 
from a high rate of cancer recurrence [7] Kidney can-
cer is the most common renal malignancy in adults 
and responsible for approximately 51,190 new cancer 
cases and accounting for 2.3% of all cancer deaths in 
the United States [8]. RCC is more prevalent in men 
than in women and occurs most often 50-70 years of 
age.  Cancer  involving  the  renal  parenchyma  (renal 
cell cancer, RCC) accounts for the majority of cases, 
while the minority of cases are usually due to cancer 
of the renal pelvis [9]. The predominant subtype of 
RCC is clear cell type that represents 80% of RCC and 
is  derived  from  the  tubular  epithelium  [10].  Other 
types of RCC are papillary (15%), chromophobe (5%), 
and collecting duct (1%). 
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The risk factors for kidney cancer are smoking, 
obesity, hypertension, kidney transplantation, family 
history of the disease and exposure to certain toxins 
[12-16]. The importance of diabetes as a potential risk 
factor for cancer has been shown in clinical and au-
topsy studies [5]. A prior history of diabetes was as-
sociated with a three-fold increased risk for cancer in 
women [14]. In the retrospective International Cancer 
Study, a 5- to 10-year history of diabetes increased the 
relative risk of cancer by 40% in both men and women 
[15]. Several mechanisms implicated in the develop-
ment  of  renal  cancer  in  diabetes  have  included  in-
creased  growth  factors  and/or  their  receptors,  hy-
perinsulinemia and glucose availability [16-20]. 
As  in  other  states  in  the  U.S.  DM  is  a  serious 
public health problem in Texas. Of the 19.3 million 
individuals in the U.S. with diabetes, more than 1.8 
million  reside  in  Texas,  with  a  high  prevalence  of 
Hispanic ethnicity [21]. Kidney cancer is one of the ten 
leading sites of cancer incidence in Texas; however, 
the association of DM and RCC histology has not been 
explored. To better understand this relationship be-
tween diabetes and renal cancer, all RCC cases at our 
center from 1994 to 2009 were analyzed with relation 
to history of diabetes, diabetic laboratory parameters 
gender, ethnicity, age and tumor morphology. 
2. Materials and Methods 
All  RCC  cases  in  patients  who  underwent  ne-
phrectomy at the University of Texas Health Science 
Center  at  San  Antonio  (UTHSC)  from  1994  to  2009 
were  analyzed  for  gender,  ethnicity  and  age  at 
presentation. Results from laboratory tests including 
HgA1C  (normal,  5.0-5.5%),  glucose  (normal,  80-100 
mg/dL) and serum creatinine (normal, 0.6-1.2 mg/dl) 
were collected. RCC subtypes were classified accord-
ing to WHO criteria. The Fuhrman nuclear grading 
system was used to classify RCC into different grades. 
Tumors were staged according to the American Joint 
Commission  on  Cancer  (AJCC)  tumor,  nodes,  and 
metastasis  (TNM)  system.  We  classified  localized 
disease as TNM Stage I: tumors ≤7 cm, limited to the 
kidney or Stage II: tumors >7 cm, limited to the kid-
ney. Regional disease included TNM Stage III: tumor 
invasion of perinephric fat or adrenal gland but not 
beyond Gerota’s facia, with or without extension into 
the renal vein or vena cava. Metastatic disease refers 
to TNM Stage IV: tumor invades beyond 
Gerota’s  fascia.  The  clinical  database  did  not 
contain  complete  information  regarding  clinical 
presentation,  type  of  DM,  and  length  of  diabetes, 
treatment  modality  or  comorbid  conditions;  thus, 
these were not included in our study. The study was 
approved by the Institutional Review Board of The 
University  of  Texas.  Health  Science  Center  at  San 
Antonio, TX. 
2.1. Statistics 
Data are presented as mean ± standard error and 
frequency counts with percentages where means were 
not  appropriate.  Where  expected  cell  counts  were 
below 5, the exact likelihood ratio chi-square test was 
used for a more appropriate statistical test of associa-
tion.  Statistical  differences  were  determined  using 
contingency table chi-square analysis and Analysis of 
Variance  (ANOVA)  followed  by  multiple  compari-
sons of subgroup means. P-values less than 0.05 were 
considered statistically significant. Software used was 
the  Statistical  Analysis  Systems’  version  9.1.3  for 
window. 
3. Results 
A total of 473 cases of RCC were identified at our 
institution  from  1994  to  2009.  Table  1  shows  that 
males comprised 56.9% of the cohort and were more 
prevalent than females (43.1%) (p=0.003). Of the RCC 
cases,  120  (25.4%)  had  a  history  of  diabetes  and, 
within  this  group,  a  greater  proportion  (p=0.01)  of 
females  (31.4%)  had  diabetes  compared  to  males 
(20.8%) (Table 1).  
 
 
Table 1: Distribution of RCC subjects with and without 
diabetes according to the gender. 
Gender 
 
RCC Cases  
Frequency (%) 
RCC+diabetes Cases  
Frequency (%) 
Male  269 (56.9)a  56 (20.8)  
Female  204 (43.1)  64 (31.4)b 
Total  473 (100)  120 (25.4)  
a. P=0.003 Unequal proportions of males and females. 




Analysis  of  RCC  cases  for  ethnic  background 
and gender together is shown in Table 2. In both RCC 
and diabetes mellitus (DM) cases with RCC, there was 
a predominance of Hispanics (63.9 and 75%, respec-
tively)  with  fewer  Whites  (28.7  and  19.2%,  respec-
tively) and Other ethnic groups (7.4 and 5.8%, respec-
tively). This is not unexpected due to the prominent 
Hispanic  population  at  our  center.  In  addition,  this 
difference may have occurred since Whites were less 
likely  to  have  diabetes  compared  to  Hispanics  and 
Other ethnicities (refer to Table 2, P=0.01). When these 
data were analyzed for an association of gender and 




male genders were not differently distributed (p=0.76) 
among the Hispanic (female 131/302, 43.4%), White 
(female  60/136,  44.1%)  and  Other  (female  13/35, 
37.4%)  ethnic  groups  (Table  2).  In  addition,  males 
were more predominant than females among all eth-
nic groups of RCC cases (Table 1, P=0.003; Table 2). In 
contrast,  in  RCC  cases  with  DM,  females  predomi-
nated  Table  2  and  the  predominance  was  similar 
(P=0.76) across all ethnic  groups [Table 2, Hispanic 
(51.1%), White (60.9%) and Other (57.1%)]. However, 
the  percentage  of  RCC  cases  with  DM  significantly 
differed  (P=0.01)  among  ethnic  groups:  Hispanics 
(90/302, 29.8%), Whites (23/136, 16.9%) and Others 
(7/35, 20%). 
Subsequently,  the  RCC  and  RCC  cases  with  a 
history of DM were further examined for an associa-
tion  with  age  and  gender.  Table  3  shows  that  the 
dominant age groups of patients with RCC were 50 to 
59 years of age (36.4%) and, to a lesser extent of 60 to 
69  (23.1%),  and  40-49  (22.3%)  years  of  age.  Within 
each  age  group,  males  consistently  predominated 
(P=0.45) compared to females for RCC cases (Table 3). 
In  contrast,  females  predominated  (64/120,  53.3%) 
compared to males (56/120, 46.7%) and were similarly 
distributed  within  age  groups  (p=0.57)  in  cases  of 
RCC  with  DM  (Table  3).  There  were  no  significant 
differences  of  male  and  female  mean  HgA1C  (P= 
0.73), serum creatinine (p=0.14) or blood glucose lev-
els (P=0.74) (Table 3). 
 
 













Total (%)  % RCC with DMc 
Hispanic  131 (43.4)  171 (56.6)  302 (63.9)   46 (51.1)  44 (48.9)  90 (75)  29.8 
White  60 (44.1)  76 (55.9)  136 (28.7)  14 (60.9)  9 (39.1)  23 (19.2)  16.9 
Other  13 (37.4)  22 (62.9)  35 (7.4)  4 (57.1)  3 (42.9)  7 (5.8)  20.0 
Total  204 (43.1)  269 (56.9)  473 (100)  64 (53.3)  56 (46.7)  120 (100)  25.4 
a. P=0.76 (gender vs ethnic group in RCC cases).  
b. P=0.76 (gender vs ethnic group in diabetic RCC cases).  
c. P=0.01 (unequal ethnic group proportions among diabetic RCC cases).  
 
 
Table 3: Distribution of RCC and RCC+diabetic subjects according to age. 
  RCCa  RCC+Diabetesb 
Age  Male  Female  Total (%)  Male  Female  Total 
30-39  31  17  48 (10.3)  9  6  15 (12.5) 
40-49  63  41  109 (22.3)  10  13  23 (19.2) 
50-59  91  79  170 (36.4)  19  29  48 (40.0) 
60-69  57  51  108 (23.1)  13  14  27 (22.5) 
70-81  23  14  37 (7.9)  5  2  7 (5.8) 
Total  265   202  467 (100)  56  64  120 (100) 
HgA1C average (%)c        7.70.37  7.50.45  7.590.30 
Creatinine average (ng/dl)d        1.420.20  1.060.14  1.220.12 
Glucose (mg/dL)e        146.610.2  146.99.4  146.86.9 
a. P= 0.45 (gender vs age group for RCC cases). 
b. P=0.57 (gender vs age group for DM cases). 
c. P= 0.73 (ANOVA, mean +/- SE). 
d. P=0.14 (ANOVA, mean +/- SE). 
e. P=0.74 (ANOVA, mean +/- SE). 
 




Next the RCC with DM cases (n=113) were ana-
lyzed for tumor morphology and size (Table 4). In this 
cohort, clear cell type (104/113, 92.0%), nuclear grade 
2  (60/107,  56.1%)  and  1-5  cm  tumor  size  (65/99, 
65.7%)  were  more  predominant  among  all  tumors. 
Analysis of the distribution of histological cell types 
among  ethnic  groups  found  significant  differences 
(P=0.01) existed (Table 4) primarily in papillary cell 
type.  Cell  chi-square  statistical  results  showed  de-
creased  papillary  cell  type  in  Hispanics  whereas  it 
increased in Whites (4/7). On the other hand, no dif-
ference in the distribution of nuclear grades (P=0.55) 
was observed across ethnic groups. The distribution 
of  tumor  size  was  significantly  different  (P=0.03) 
among ethnic groups due to decreased frequency of 
small  (1-5  cm)  and  increased  frequency  of  medium 
(>5-10 cm) tumors in the Other ethnic group (Table 4). 
Interestingly,  average  of  HgA1C  was  significantly 
higher  (P=0.05)  in  Hispanic  patients  compared  to 
Whites  and  Other  ethnicities  (Table  4)  by  the  least 
significant difference (LSD) pairwise comparison test 
following  a  one-way  ANOVA.  Blood  glucose  and 
creatinine mean values were not significantly differ-
ent for the ethnic groups (P=0.84 and P=0.88, respec-
tively). 
To identify the association between tumor sizes 
within the RCC diabetic cohort, we analyzed all RCC 
diabetic subjects for tumor size and diabetic parame-
ters. Data in Table 5 show that total of 65 cases have 
tumor size 1-5 cm, 31 cases with >5-10 cm and 3 cases 
with >10cm. Interestingly, the average of HgA1C was 
significantly higher (8.1, P=0.05) in patients with tu-
mor  size  1-5  cm  compared  to  tumor  size  >5-10  cm 
(Table 5). In addition, the average of glucose level was 
slightly higher in patients with tumor size of 1-5 cm; 
however, significant differences among the tumor size 
groups  for  serum  glucose  and  creatinine  were  not 
detected (Table 5). 
 The  association  between  tumor  stage,  HgA1C, 
creatinine and glucose levels among all ethnic groups 
is shown in Table 6. Among all ethnic groups, tumor 
stage  I  was  the  predominant  stage  (79/109,  72.5%) 
compared to advanced stage III (22/109, 20.2%) and 
IV (5/109, 4.6%) (Table 6). Interestingly, the HgA1C 
average (8.2) was higher in patients with tumor stage 
IV  compared  to  patients  with  other  tumor  stages, 
although this was not statistically significant. In addi-
tion, tumor stage was significantly associated with the 
ethnicity (P=0.03) due to small frequency differences 
(Whites had decreased Stage III and Others had in-
creased Stage II), whereas no significant association 
was identified between creatinine and glucose levels 
and tumor stages (Table 6). 
 
Table 4: Distribution of RCC diabetic subjects according to cell type, nuclear grade, tumor size and HgA1C. 
Ethnicity  Hispanic  White  Other  Total (%) 
Number  86  20  7  113(100) 
Histological Cell type         
Clear cell  83  16  5  104 (92.0)a 
Papillary  2  4  1  7 (6.2) 
Chromophobe  1  0  1  2 (1.8) 
Nuclear grade         
1  19  4  0  23 (21.5) 
2  45  12  3  60 (56.1)b 
3  14  3  3  20(18.7) 
4  3  1  0  4 (3.7) 
Tumor size         
1-5 cm  54  11  0  65 (65.7) 
>5-10 cm  23  4  4  31 (31.3)c 
>10 cm  3  0  0  3 (3.0) 
HgA1C averaged  8.0  6.1  6.3   
Glucosee  148.4  146.1  131.4   
Creatininef  1.2  1.3  1.1   
a. P=0.01 (Ethnicity vs cell type). 
b. P=0.55 (Ethnicity vs nuclear grade). 
c. P=0.03 (Ethnicity vs tumor size.) 
d. P=0.05 (for Hispanics vs Whites following ANOVA with p=0.11). 
e. P=0.84 (ANOVA). 




Table 5: Association of tumor size with diabetic parameters. 
Tumor sizea  Hispanic  White  Other  Total (%)   HgA1Cb  Creatininec  Glucosed 
 1-5 cm  54  11  0  65 (65.7)  8.1  1.10  148.7 
 >5-10 cm  23  4  4  31 (31.3)  6.7  1.34  146.6 
 >10 cm  3  0  0  3 (3.0)  5.5  0.95  85.0 
a. P=0.03 (Ethnicity vs tumor size). 
b. P=0.11, ANOVA, but only 1-5 cm vs >5-10 cm p=0.05; 1-5 cm vs >10 cm p=0.30. 
c. P=0.68 (ANOVA). 
d. P=0.49 (ANOVA). 
 
Table 6: Association of tumor stage with diabetic parameters. 
Tumor stagea  Hispanic  White  Other  Total (%)   HgA1Cb  Creatininec  Glucose (mg/dL)d 
I  60  16  3  79 (72.5)  7.61  1.18  148.3 
II  1  1  1  3 (2.7)  5.90  1.15  107.5 
III  21  0  1  22 (20.2)  7.66  1.14  147.2 
IV  4  1  0  5 (4.6)  8.20  0.73  144.0 
Total  86  18  5  109 (100)       
a. P=0.03 (Ethnicity vs tumor stage). 
b. P=0.90 (ANOVA). 
c. P=0.91 (ANOVA). 
d. P=0.90 (ANOVA). 
 
4. Discussion 
This is the first report to characterize RCC cases 
in a South Texas population with respect to ethnicity, 
age, gender, laboratory parameters and tumor mor-
phology. Our data indicate that a high proportion of 
RCC cases are associated with diabetes (25.4%), sug-
gesting that diabetes one of the factors for the devel-
opment of RCC. At our institution, when RCC sub-
jects were screened for a history of diabetes, we ob-
served a higher incidence of diabetes in female RCC 
subjects compared to male subjects. RCC cases with 
diabetes were also more prevalent in Hispanics com-
pared to White and Other subjects and the majority of 
diabetic patients were diagnosed with RCC at 50-59 
years of age. In addition, diabetic RCC patients had a 
predominance  of  the  clear  cell  type  RCC,  nuclear 
grade II, tumor size 1-5 cm and tumor stage I. The 
average  HgA1C  level  was  significantly  higher  in 
Hispanic  patients  compared  to  Whites  and  Other 
ethnicities. Moreover, the average HgA1C level was 
higher in patients with tumors size 1-5 compared to 
those >5-10 cm. The high incidence of localized cancer 
may be largely due to the increased incidental detec-
tion of RCC through the ultrasound and CT for non-
renal cancer-related problems [22-24]. 
RCC is the most common renal malignancy in 
adults, with a greater incidence in males than females 
and  average  age  at  diagnosis  in  the  early  60s  [25]. 
Similarly, the incidence of RCC was predominated in 
males dominant age range at presentation being 50-59 
years. This is slightly younger than the mean age of 
presentation reported by most case series and may be 
due to early detection within our population. A simi-
lar  age range  was  observed  in  our  RCC  cases  with 
diabetes;  however,  females  were  more  prevalent, 
consistent  with  other  series.  In  a  previous  study,  a 
prior  history  of  diabetes  was  associated  with  a 
three-fold increase in the relative risk for renal cancer 
in women [21]. These findings indicate that the gen-
der distribution of diabetic RCC is different from its 
nondiabetic  counterpart,  suggesting  that  there  may 
also be differences in the biology of RCC in these pa-
tients. 
Adult  RCC  has  been  demonstrated  to  have  a 
slightly greater incidence in African Americans than 
in Whites [26]. Our data shows that the majority of 
RCC  patients  with  or  without  a  history  of  diabetes 
have Hispanic backgrounds. Few studies have exam-
ined cancer in U.S. Hispanics, and results showed that 
the incidence of kidney cancer varies depending on 
the  geographic  location  of  the  Hispanic  population 
analyzed [27,28]. In South Texas, Hispanics comprise 
a large portion of the population and the prevalence 
rate  of  diabetes  in  Mexican  Americans  is  1.9  fold 
higher than that in non-Hispanic Whites. Moreover, 
our  study  supports  the  observation  that  Hispanics 




[29]. In epidemiological and autopsy studies, elevated 
fasting serum glucose and diabetes were risk factors 
for the development of cancer in several organs in-
cluding kidney [18] and the risk of cancer has been 
reported to increase in proportion to HgA1C levels in 
diabetes [13,14]. 
Several studies showed that Hispanics  popula-
tion have higher prevalence of obesity, type 2 diabe-
tes,  and  high  fat  diet  than  non-Hispanic  Whites 
[27,29,30]. These factors may play a major role in in-
crease the incidence RCC There is evidence of a posi-
tive  association  between  obesity  and  risk  of  RCC 
[31,32].  We  could  not  differentiate  the  type  of  DM, 
although most cases among adults would be expected 
to be type 2. Laboratory values were obtained near the 
time  of  nephrectomy  and  represented  the  fasting 
glucose levels of all patients but lacked information 
regarding the body mass index, duration of diabetes, 
follow up the laboratory values and treatment. Such 
information is important for determining whether the 
severity and duration of  diabetes is correlated with 
risk  of  developing  RCC.  Nevertheless,  our  findings 
showed that HgA1C values were significantly higher 
in patients with tumors 1-5 cm compared to >5-10 cm, 
suggesting that HgA1C may provide a useful marker 
for early detection of silent or small RCC before they 
manifest clinically. Serum glucose or creatinine levels 
were not associated with tumor size or stage. In pre-
vious studies, the incidence of end-stage renal disease 
due to DM was higher in minorities including His-
panics  [30];  however,  in  our  cohort,  little  or  no  in-
crease in serum creatinine was observed at the time of 
nephrectomy. 
 The  predominant  subtype  of  RCC  is  clear  cell 
type that represents 80% of RCC and is derived from 
the tubular epithelium [10]. Our data show that ma-
jority  of  tumors  (92%,  P=0.01)  was  clear  cell  type 
among  all  ethnic  groups  in  RCC  diabetic  patients 
suggesting  that  diabetes  may  involve  an  increased 
risk of development of clear cell type tumor. Recent 
work in the molecular pathogenesis of clear cell RCC 
has facilitated the development of therapeutic strate-
gies to target this tumor type. However, few studies 
have examined who is at increased risk for this histo-
logic variant. Obesity is associated with a higher risk 
of clear cell RCC than with other histologies [6,12,32]. 
Our  results  provide  the  first  evidence  that  diabetic 
RCC patients have a predominance of clear cell sub-
type with nuclear grade 2. In 98% of these tumors, 
whether  familial,  sporadic  or  associated  with  Von 
Hippel-Lindau (VHL) syndrome, they typically result 
from  a  somatic  mutation  within  the  VHL  tu-
mor-suppressor  gene  found  on  the  short  arm  of 
chromosome  3  3p25  [18,  19,  32].  Mutation  of  VHL 
activates  hypoxia-inducible  factor-1  (HIF-1),  leading 
to  increased  transcription  of  pro-angiogenic  factors 
including  PDGF  and  VEGF  that  play  a  key  role  in 
renal  cell  tumorigenesis.  In  diabetic  patients,  other 
pathogenetic mechanisms previously described may 
also contribute to clear cell RCC including: prolonged 
exposure to pro-insulin products with some homol-
ogy to IGF-1, raised growth factors and growth factor 
receptors,  increased  endogenous  estrogen  levels, 
end-stage renal disease due to diabetic nephropathy 
and  hypertension  [5].  Interestingly,  histologic  type 
varied among ethnic groups, with papillary cell type 
increased in Whites, but decreased in Hispanics. Per-
haps this reflects differences in the tumor biology or 
genetics in various ethnic groups. 
The incidence of all  stages of kidney cancer is 
increasing  in  the  U.S.,  particularly  T1  disease  and 
primarily  reflects  small  tumors  discovered  inci-
dentally  on  abdominal  imaging  [33].  In  agreement 
with this finding, our cohort of RCC cases with DM 
showed  a  predominance  of  tumor  size  1-5  cm  and, 
among all ethnic groups, stage I was more commonly 
observed  than  other  stages.  Tumor  size  and  stage 
were  associated  with  ethnicity  as  evidenced  by  a 
greater incidence of medium size (>5-10 cm) tumors 
and  stage  2  in  Other  ethnicities  and  a  reduction  in 
stage 3 tumors in Whites. It is tempting to speculate 
that  African  Americans  within  the  “Other”  group, 
reported  to  have  more  aggressive  disease  than 
Whites, may have contributed to this ethnic diversity 
[33,34].  Tumor  staging  in  adult  RCC  is  a  strong 
prognostic indicator and the presence of lower-stage 
tumors in DM patients suggests a favorable response 
to  therapy  and  survival.  Although  HgA1C  was 
slightly higher in patients with stage IV, we did not 
observe a statically significant association of HgA1C, 
blood glucose or creatinine with tumor stage. Further 
studies  with  larger  cohorts  of  DM  patients  will  be 
useful for increasing our understanding of the associ-
ation of DM with clear cell RCC. 
In conclusion, our findings indicate that diabetic 
RCC patients have a predominance of localized, small 
clear cell RCC. Prospective studies are needed to fur-
ther evaluate the importance of glycemic control and 
effective reduction of glucose levels on the outcome of 
RCC. In addition, the results of our study may have 
implications  in  determining  a  patient’s  risk  of  har-
boring a clear cell RCC and subsequent therapeutic 
recommendations. 
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